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Background
Parkin is associated to autosomal recessive early-onset
Parkinson’s disease. Parkin acts as an E3-ubiquitin ligase
involved in the proteasome-mediated degradation of var-
ious substrates. It has been suggested that pathogenic
mutations of parkin, abolishing its ubiquitin-ligase activ-
ity, could explain the accumulation of proteins and lead
to neuronal death by apoptosis. However, besides this
function, additional parkin-dependent cellular pathways
exist. We demonstrated that parkin is a direct transcrip-
tional repressor of the tumor suppressor p53 [1]. p53
regulates the expression and functions of presenilin-1
(PS1) and presenilin-2 (PS2), two members of the
gamma secretase complex involved in the production of
the amyloid b peptide (Ab) and parkin could control the
homeostasis of intracellular Ab. These findings
prompted us to investigate whether parkin could control
presenilins and if so, whether it is via a direct transcrip-
tional control of PS promoters or indirectly, via p53.
Materials and methods
Experiments were conducted on TSM1 neurons, SH-
SY5Y human neuroblastoma cells, human embryonic
kidney 293 cells, and immortalized mouse embryonic
fibroblasts invalidated or not for parkin, presenilin
1 and/or 2, p19arf and both p19arf p53. We also used
primary cultured neurons and brain extract from mouse
invalidated or not for parkin.
We did Q-PCR, Western-blot, caspases-3 activity
measurement and in vitro gamma secretase assays
experiments. We document by chromosome immune-
precipitation, gel shift, gene reporter and mutagenesis
experiments parkin direct interaction with presenilins
promoters.
Results
Parkin controls presenilin 1 and 2 expressions, promoter
activity, and mRNA levels ex vivo and in mouse brains.
This regulation impacts on PS-dependent g-secretase
activity and presenilin-mediated control of cell death.
This control is independent of parkin ubiquitin-ligase
activity, does not involve p53 and is not affected by PS1
and PS2 functional interplay. Parkin binds to presenilins
promoters via a consensus binding sequence that we
identify and validate by functional analysis [2].
Conclusions
This study is a “framework” for the identification of
novel transcriptional targets of parkin and for a better
comprehension of parkin’s functions.
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